Amgen — Third Quarter 2026 Earnings Summary

Amgen reported third-quarter 2026 total revenues of $10.4 billion, an 8% increase year-over-year, driven by volume growth across its commercial portfolio. GAAP earnings per share rose 19% to $7.08, while non-GAAP EPS increased 14% to $6.45, supported by a 9.9 percentage point expansion in GAAP operating margin to 37.5%. Key product performance included significant sales growth for Repatha, EVENITY, UPLIZNA, and IMDELLTRA, though Prolia and XGEVA sales declined due to biosimilar competition. The company generated $3.7 billion in free cash flow for the quarter and provided full-year 2026 revenue guidance between $38.9 billion and $39.7 billion.